ClinicalTrials.gg
Not yet recruitingNCT07002840Updated Jun 4, 2025

Effect of Cross-legged Sitting Among Patients With Unilateral Hip Developmental Dysplasia

An interventional study of Cross- legged sitting position and Physical Therapy Rehabilitation Program in Hip Developmental Dysplasia, sponsored by Jouf University. Not yet recruiting. Open to participants aged 9 Months to 10 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Jouf University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
9 Months to 10 Years
Sex
All
01

Study summary

One of the most common infant developmental diseases is Hip dysplasia which is mostly seen among female' babies and leads to hip instability due to partial or full hip dislocation [1]. Physical therapy's role plays a significant role in treating hip dysplasia by creating new walking habits as an adaptation way and compensation for the deformity [3]. Focusing on the muscles that produce hip abduction force is a basic item of the hip dysplasia rehabilitation program [4]. Cross-legged sitting position can be considered as a common and easy position that might enhance the range of motion of the lower limb joints [5].

While unilateral hip developmental dysplasia has been widely distributed among newborns, especially in the last few years, the role of engaging the cross-legged sitting technique as a part of physical therapy and rehabilitation programs on improving the temporospatial parameters, muscular electrical activity and foot pressure distributing is still not clear. Therefore, this study aimed to analyze the effects of engaging the cross-legged sitting technique as a part of physical therapy and rehabilitation program among patients with UHDD by comparing the group who participated in rehabilitation program with CLS to the other without.

To understand the importance of including Cross-legged sitting technique in physical therapy and rehabilitation program of Unilateral Hip Developmental Dysplasia (UHDD) to enhance the spatial and temporal measures, achieving a healthy distribution of foot pressure, increasing the electrical activity of lower limb muscles and improving the overall gait pattern.

No risks at all. All instruments and techniques in this study are safe and used regularly without any hazards.

The data will be stored and archived on a password-protected computer for safety and security purposes. After accomplishing the research and getting the outcomes, the results of the research may be published as an academic article in a peer-reviewed journal. In another word, no personal data will be published at all.

Taking part in the study and withdrawing at any time is completely voluntary with no need to give any reason.

02

Conditions studied

  • Hip Developmental Dysplasia

Keywords

  • Rehabilitation
  • Gait
  • Foot pressure
  • Hip Developmental Dysplasia
03

In context

Developmental Dysplasia of the Hip

60 studies on the registry are indexed under Developmental Dysplasia of the Hip; 18 are open to participants now.

This study's planned enrollment of 16 is below the median of 59 across 38 interventional studies indexed under Developmental Dysplasia of the Hip.

Browse Developmental Dysplasia of the Hip studies →

Lead sponsor

Jouf University is the lead sponsor of 22 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Months to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age group from 9 months to 10 years old
  • all participants suffer from Unilateral Hip Developmental Dysplasia (UHDD)
  • participants should be healthy in general

Exclusion criteria

Exclusion Criteria:

Any participant with a history of neurological disorders, lower extremities previous surgical intervention, lower limb deformities, flat feet or high will be excluded from this study

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    DDH kids who participated in rehabilitation programs with CLS

    The study sample includes kids with DDH who participated in rehabilitation programs with CLS.

    Other: Cross- legged sitting position · Other: Physical Therapy Rehabilitation Program

  • Active comparator
    DDH kids who participated in usual rehabilitation programs without CLS

    The study sample includes kids with DDH who participated in rehabilitation programs without CLS.

    Other: Physical Therapy Rehabilitation Program

Interventions

  • OtherCross- legged sitting position

    CLS in which the legs were crossed with hip and knee joints flexed

  • OtherPhysical Therapy Rehabilitation Program

    Strengthening Exercises Stretching Exercises Range of Motion Exercises

06

What researchers measure

Primary outcomes

  1. Gait Temporospatial Parameters

    Cadence will be measured by Gait Rite

    Time frame: 3 months

  2. Muscle Electrical Activity

    Muscle Electrical Activity will be measured by Electromygraphy

    Time frame: 3 months

Secondary outcomes

  1. Foot Pressure

    Average pressure will be measured using the foot pressure system

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2025, 6 months later.

Of 20 interventional studies with no phase under Developmental Dysplasia of the Hip, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
Jun 4, 2025
StartEst.
Jun 5, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07002840
Lead sponsor
Jouf University
Responsible party
Hadeel Saad Alsirhani (Assistant Professor of Physical Therapy, Jouf University) — Principal investigator
First posted
Jun 4, 2025
Start date
Jun 5, 2025 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jun 4, 2025

Study contacts

Hadeel Alsirhani, PhD
Contact
hsalserhany@ju.edu.sa
+966556256464

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion